The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.
Carcinoma|Non-Small-Cell Lung Carcinoma|Head and Neck Neoplasms
DRUG: AZD2171
Change From Baseline in Standardised Uptake Value (SUVmax) as Measured by 2-[F-18]-Fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET), Percentage Change from baseline in Standardised Uptake Value (SUVmax) at Day 22, as Measured by 2-\[F-18\]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) Response ((Day 22 SUVmax value - baseline SUVmax value)/baseline SUVmax value)\*100, Randomisation until Day 22
Change From Baseline in Mean Arterial Blood Pressure (MAP), Change from baseline in mean arterial blood pressure (MAP) (MAP value at Day 22 - MAP value at baseline)., Randomisation until Day 22
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.